Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

New board member of CLS buys shares in the company and the CEO and EVP Operations increase their shareholdings

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company's new Board member Peter Mantas, the CEO, Dan J. Mogren, and EVP Operations, Jimmy Johansson, have purchased a total of 22,000 Class B shares in CLS.Peter Mantas acquired 10,000 shares bringing his total holding to 10,000 Class B shares on Wednesday, November 6th. Dan J. Mogren completed the purchase of 8,000 shares on November 5th. After the transactions, Dan J. Mogren's total holding amounts to 30,939 Class B shares plus 632 Class B shares via Medinovus AB. Jimmy

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 239 – 6 NOVEMBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 235/24 and 237/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Therese Möllevinge, Head of Investor Relations, tel.: +45 41 37 16 38, e-mail: thm@norden.com Isabella Zaugg Hansen, Investor Relations Manager, tel.: +45 27 62 90 96, e-mail: izh@norden.com

SAS achieves landmark IATA IEnvA assessment certification

SAS has received official approval of its IEnvA Assessment Report, marking a significant milestone in the company’s commitment to environmental sustainability.As the aviation industry faces growing concerns regarding its environmental footprint, SAS leads in sustainable practices, continuously updating its Environmental Management System to align with industry standards. This achievement not only highlights SAS leadership in environmental stewardship but also serves as a model for others in the industry.  “SAS is the first airline within the SkyTeam alliance to receive the IATA IEnvA

CasinoRank Unveils Comprehensive Analysis of the Best Crash Games with Demo Play

Stockholm, Sweden, November 2024 – MobileCasinoRank, a leading platform in mobile casino content and reviews is excited to present its latest analysis of the best crash games of 2024, now with a new Demo Play option available on its website. This feature allows users to try popular crash games for free, providing an opportunity to experience these high-risk, high-reward games without wagering real money. The report offers valuable insights into top titles captivating mobile casino players, such as Aviator by Spribe, Spaceman by Pragmatic Play, Big Bass Crash, Astronaut, and Cash Or Crash Live.

Gentoo Media: Invitation to Q3 2024 results presentation

Gentoo Media Inc. publishes its interim report for the third quarter 2024 before market opening on Wednesday 13 November 2024. Jonas Warrer, CEO, will host a presentation of the Q3 2024 results via livestream at 09:00 CET. The presentation will be followed by a Q&A-session, and investors, analysts and journalists are welcome to participate. The presentation will be given in English. Link to the livestream:https://www.redeye.se/events/1045411/live-q-gentoo-media For further information, please contact:Tore Formo, Group CFO, tore.formo@g2m.com, +47 91668678 About Gentoo Media

Navamedic launches Eroxon[®] in Finland

Oslo, 6 November 2024 – Building on the successful product launch of Eroxon[®] in Norway and Sweden earlier this year, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, is now launching Eroxon[®] across pharmacies in Finland. Eroxon[®] will be the first clinically proven over-the-counter topical treatment for the treatment of erectile dysfunction in men in Finland.Eroxon[®] is part of Navamedic’s increasingly growing Consumer Health category. Since the product launched in Norway in February 2024, Eroxon[®] has

AddSecure officially launches alarm signalling services in the UK

Focused on ensuring the seamless continuity of the Next Generation Portfolio, AddSecure provides uninterrupted service to its customersAddSecure , a leading European provider of secure IoT connectivity and end-to-end solutions with a special focus on alarm signalling solutions, today announced the official launch of its operations in the UK market. This launch marks a significant milestone for AddSecure as it continues to expand its presence and offerings in the industry.   As part of this launch, AddSecure is introducing the Next Generation Portfolio (

Read original

NIB in Q1-Q3: Stable financial results with high increase in new signed lending

During the first nine months of 2024, the Nordic Investment Bank (NIB) delivered net profit of EUR 198 million (EUR 195 million in the same period in 2023) and disbursed EUR 2.4 billion (EUR 2.0 billion). NIB’s new signed lending increased to EUR 3.2 billion compared to EUR 1.6 billion the same period last year.During the third quarter, new lending was distributed across various sectors and countries and will finance investments in energy sector, digital transformation, and research and development, for example.“Our financial performance and high level of activity indicates a good

The exercise period for subscription of shares through exercise of warrants of series TO5 begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, 6 November 2024, the exercise period for warrants of series TO5 (“TO5”) in PEPTONIC medical AB ("Peptonic" or “the Company”) begins. The exercise period runs from and including November 6, 2024, until and including November 20, 2024. Each TO5 entitles

In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Diamyd Medical will present new analysis results on November 7 at the 20th Immunology of Diabetes Society (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness of the treatment effects and underscore the potential for precision medicine to slow and delay disease progression in Type 1 Diabetes.”These analyses clarify the robustness of our previous treatment results across trials in our genetically defined responder patient group, and further characterize the effect of Diamyd[®] on glycemic control”,

PHI's new CEO to BioStock: "I am excited to lead us forward with new energy"

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. We spoke with him about his vision for the future.Read the full interview with Anders Månsson at biostock.se: https://www.biostock.se/en/2024/11/phis-new-ceo-i-am-excited-to-lead-us-forward-with-new-energy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Announcement of a Change in Shareholding According to Chapter 9, Section 10 of the Finnish Securities Market Act

Sitowise Group Plc Stock Exchange Release 6 November 2024 at 9.45 a.m. (EET) Sitowise Group Plc (the "Company") has on 5 November 2024 received a notification in accordance with the Chapter 9, Section 10 of the Finnish Securities Market Act from Morgan Stanley, according to which Morgan Stanley & Co International Plc's holding of the shares and votes of the Company has increased above 5.00 percent on 4 November 2024. According to the notification, Morgan Stanley holds indirectly a total of 46,560 shares corresponding to 0.13 percent of the Company’s shares and votes, and a total of 2,

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health Plc Press release 6 November 2024 at 09:45 a.m. (EET)   Nightingale Health, a pioneer in disease risk detection and preventative health has appointed internationally recognised expert in medicine Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK.   Dr. Charles Alessi is a physician with more than 35 years of experience in all aspects of policy and clinical practice in the United Kingdom, Northern Ireland and globally. Alessi’s experience includes key positions in some of the world leading organisations in the industry, such as acting

NYAB AB’s Interim Report January-September 2024: Doubled order backlog and strong profit improvement

· Solid revenue growth and strong project execution · Improved operating margins and net profit · Favorable market conditions resulting in a record-high order backlog July-September in brief · Revenue amounted to EUR 93.6 (88.1) million, representing a change of 6.2%. In constant currencies, revenue growth was 4.2%. · Operating profit (EBIT) improved 35.4% and was EUR 8.9 (6.6) million, amounting to 9.5% (7.5%) of revenue. · Free cash flow was EUR -8.3 (-3.8) million. · Net debt/EBITDA was 0.06 (0.30). · Order backlog improved 108.4% and amounted to EUR 381.9 (183.

Aixia continues to grow with a new client in property management and aims for future AI business

Mölndal                                                                                      2024-11-06 Aixia has signed a significant agreement with a new customer in property management. This collaboration marks a strategic step forward for Aixia, as the company sees great opportunities to introduce AI solutions in this industry In the new assignment, Aixia's expertise will take overall responsibility for the customer's operating environment, drive important improvement projects and ensure that the IT architecture is optimized for the demands and needs of the future. The

BioStock: Cereno Scientific’s CEO on novel therapies for rare diseases

BioStock met with Cereno Scientifics CEO Sten R. Sörensen at BioEurope. Cereno Scientific is developing novel therapies for rare diseases, with a mission to bring innovative treatments to enhance and extend the lives of patients with high unmet medical needs. In this interview, Sten shares insights on the company’s current projects, their objectives at BioEurope, and the future ahead.Watch the interview with Cereno Scientific at biostock.se:https://www.biostock.se/en/2024/11/cereno-scientifics-ceo-on-novel-therapies-for-rare-diseases/This is a press release from BioStock - Connecting

Invitation to presentation of BioArctic’s third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET

Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on November 14, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the third quarter report, followed by a Q&A-session. If you wish to participate via webcast, please use the link below. Via the webcast you

Compressor distributor in Türkiye has become part of Atlas Copco Group

Nacka, Sweden, November 6, 2024: SCS Makina A.Ş. (“SCS”), an independent compressor distributor located in Adana, Türkiye, has become part of Atlas Copco Group.SCS was founded in 2011 and has 11 employees. The company provides sales and service of air compressor solutions to the Turkish market and is focused on the textile, cement, chemicals, and food & beverage sectors. “With this acquisition we will be able to grow our geographical presence further and serve current and future customers even better”, said Philippe Ernens, Business Area President Compressor Technique. During 2023 the

The subscription period in Crunchfish’s rights issue begins today and the company invites to a webinar about the rights issue

Today, November 6th, 2024, the subscription period in Crunchfish AB’s (“Crunchfish” or the “Company”) rights issue of units of approximately SEK 57 million before issue costs (the “Rights Issue”) begins. The Rights Issue is covered by subscription commitments and guarantee commitments up to approximately 45 percent from larger shareholders and external investors. The Rights Issue was approved at the Extraordinary General Meeting held on October 24, 2024. All interested parties are invited to a webinar about the Rights Issue on November 11th, 2024, where the audience will have the opportunity

Interim report January – September 2024

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value at the end of the period was SEK 216 per share compared with SEK 198 per share at the start of the year, which is an increase of 11.3 per cent adjusted for dividends. The benchmark index (SIXRX) rose 15.2 per cent. The net asset value was SEK 218 per share at 5 November.[1] · The total return on the Latour share was 22.5 per cent measured against the SIXRX, which increased 15.2 per cent. INDUSTRIAL OPERATIONS The third quarter · The industrial operations’ order intake rose 3 per cent to SEK 5,739 m (5,565 m), a 2

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q3 2024

"During the third quarter, the trend of good growth continued for our consumer brands, while our industrial products continued to face a challenging market situation. Despite a sales decrease of -14 (50) percent to MSEK 28.9 (33.4) during the quarter, our operating profit/loss was in line with the third quarter of 2023 at MSEK -3.0 (-2.8), thanks to the changed product mix and sound cost control. For the first nine months of the year (Jan–Sept), the operating profit/loss was also in line with the previous year at MSEK -3.0 (-3.1), while cash flow from operating activities was significantly

GomSpace signs 325.000€ contract change notice for Juventas mission

This week, GomSpace and the European Space Agency (ESA) has signed a contract change notice of 325.000€ (3.8MSEK) to support additional project activities.Further strengthening the relationship in the frame of the HERA mission and on the Juventas spacecraft, GomSpace and ESA signed a contract amendment for 325.000€, which will take full effect this year. The amendment aims to support activities adding particular value to the long-term exploitation of the mission as well as during the initial launch phases. “All HERA mission participants have worked hard to get ready for the mission

Two thousand square meters let at Kaserntorget 6

Wallenstam’s initiative involving reuse, green leases and full-service offices ready for occupation at Kaserntorget 6 has been highly sought after. Recently, Prodesign signed an agreement for the last premises of 460 square meters and will move in during January next year. This means that the entire property of about 2,000 square meters in total is now fully let.“Kaserntorget 6 has been an exciting project. Two thousand square meters of office space where we offer our customers a comprehensive solution, which is ready for occupation, featuring wireless connectivity, meeting technology,

There are no items matching the current filter
There are no more items matching the current filter
Back to top